Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL

Lymphoma Non-Hodgkin Clinical Trial

Official title:

Open-label, Uncontrolled, Single-arm, Phase Ib/II Study of Intravenous Copanlisib in Japanese Patients With Indolent B-cell Non Hodgkin's Lymphomas Relapsed After or Refractory to Standard Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02342665
• Other study ID #: 17792
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: April 21, 2015
• Est. completion date: February 10, 2022

Study information

• Verified date: January 2023
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to assess the safety profile of copanlisib at the recommended dose (primary endpoint). The recommended dose of copanlisib for Japanese patients will be determined in the dose escalation/safety evaluation part.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: February 10, 2022
• Est. primary completion date: September 14, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed diagnosis of indolent B-cell NHL, with histological subtype limited to the following:

Follicular lymphoma (FL) grade 1-2-3a Small lymphocytic lymphoma (SLL) with absolute lymphocyte count < 5 x 109/L at the time of diagnosis and at study entry Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM) Marginal zone lymphoma (MZL) (splenic, nodal, or extra-nodal)

• Relapsed or refractory after = 2 prior lines of therapy (refractory defined as not responding to a standard regimen or progressing within 6 months of the last course of a standard regimen). Patients must have previously received rituximab and alkylating agent(s).

• Japanese patients = 20 years of age

• ECOG performance status = 2 (Eastern Cooperative Oncology Group:ECOG)

• Life expectancy of at least 3 months

• Adequate bone marrow, liver and renal function as assessed within 7 days before starting study treatment

• Left ventricular ejection fraction (LVEF) = lower limit of normal (LLN) for the Institution

• Availability of fresh or archival tumor tissue

Exclusion Criteria:

• Uncontrolled hypertension (blood pressure = 150/90 mmHg, defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 90 mmHg, despite optimal medical management)

• Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event = CTCAE Grade 3 (NCI-CTC version 4.0) within 4 weeks of start of study medication (CTCAE: Common Terminology Criteria for Adverse Events, NCI: National Cancer Institute).

• History or concurrent condition of interstitial lung disease or severely impaired pulmonary function

• Unresolved toxicity higher than CTCAE grade 1 attributed to any prior therapy/procedure excluding alopecia.

• Prior treatment with PI3K inhibitors

• Systemic corticosteroid therapy (ongoing)

• Type I or II diabetes mellitus with HbA1c > 8.5% or fasting plasma glucose > 160 mg/dL at Screening

• Known history of human immunodeficiency virus (HIV) infection.

• Hepatitis B or C requiring treatment

• Cytomegalovirus (CMV) PCR positive at baseline

• Known lymphomatous involvement of the central nervous system

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma Non-Hodgkin

Intervention

Drug:
• Copanlisib (BAY80-6946)
Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with Adverse Events		Up to 18 months
Primary	Intensity of AE	The NCI Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0) will be used to assess the intensity of AE	Up to 18 months
Primary	Objective Tumor Response (OR)	OR: Best response rating of complete response or partial response according to the criteria defined in the Revised Response Criteria for Malignant Lymphoma(JClin Oncol.2007 Feb)	Up to 18 Years
Primary	Recommended dose determined in the dose escalation/safety evaluation		Up to 18 months

External Links

•   Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.